<DOC>
	<DOCNO>NCT02001480</DOCNO>
	<brief_summary>Aim : Patients type 2 diabetes mellitus ( T2DM ) hemodialysis due diabetic nephropathy exhibit high risk sudden cardiac death ( SCD ) . Preliminary data suggest beta-blocker treatment may reduce arrhythmias mortality high-risk population . However , result large-scale clinical outcome trial beta-blockers exist patient group broad , scientifically unapproved use beta-blocker treatment may justify due potential harmful side-effects AV-block hypotension . In addition , lack identify ECG surrogate parameter SCD high-risk population occurrence arrhythmia temporary relationship hemodialysis session . Therefore , present study identify surrogate parameter SCD hemodialysis patient T2DM interventional trial investigate suppressive effect beta-blockers identify ECG marker .</brief_summary>
	<brief_title>Surrogate Markers Sudden Cardiac Death Patients With Diabetes Mellitus End Stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>patient diabetes mellitus type 2 chronic hemodialysis least since 3 month age 18 year write informed consent legally competent intake betsblockker within last four week pregnancy breast feed abuse drug alcohol miss compliance life expectancy &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>